This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
MGMT Monoclonal Antibody (MT 3.1), Biotin
catalog :
MA5-13503
quantity :
500 µL
price :
US 487.00
clonality :
monoclonal
host :
mouse
conjugate :
biotin
clone name :
MT 3.1
reactivity :
human, mouse
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section
citations: 57
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry; human
Deb P, Mani N, Sudumbrekar S, Taneja N, Patrikar S. Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas. Med J Armed Forces India. 2013;69:228-36 pubmed publisher
  • immunohistochemistry; human; 1:40
Chang I, Hsu C, Lin J, Hung C. The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study. Folia Neuropathol. 2013;51:275-82 pubmed
  • immunohistochemistry; human; 1:50
Lee E, Lee B, Ko E, Kim Y, Han J, Shim Y, et al. Cohypermethylation of p14 in combination with CADM1 or DCC as a recurrence-related prognostic indicator in stage I esophageal squamous cell carcinoma. Cancer. 2013;119:1752-60 pubmed publisher
  • immunohistochemistry; human; 1:100
Park C, Kim J, Kim J, Song S, Kim J, Choi S, et al. The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. Transl Oncol. 2012;5:393-7 pubmed
  • immunohistochemistry; human; 1:170
von Bueren A, Bacolod M, Hagel C, Heinimann K, Fedier A, Kordes U, et al. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. Br J Cancer. 2012;107:1399-408 pubmed publisher
  • western blot; human
Caldera V, Mellai M, Annovazzi L, Monzeglio O, Piazzi A, Schiffer D. MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. Cancer Genomics Proteomics. 2012;9:171-8 pubmed
  • immunohistochemistry; human
Sano K, Toda M, Sasaki H, Kitamura Y, Mikami S, Hirato J, et al. Infratentorial low-grade oligoastrocytoma with aggressive clinical behavior in an adult: a case report with genetic characterization. Brain Tumor Pathol. 2013;30:99-103 pubmed publisher
  • immunohistochemistry; human; 1:100
Oka H, Utsuki S, Tanizaki Y, Hagiwara H, Miyajima Y, Sato K, et al. Clinicopathological features of human brainstem gliomas. Brain Tumor Pathol. 2013;30:1-7 pubmed publisher
  • immunohistochemistry; human; 1:20
Takano S, Kato Y, Yamamoto T, Kaneko M, Ishikawa E, Tsujimoto Y, et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol. 2012;108:361-73 pubmed publisher
  • western blot; mouse; 1:400
Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, et al. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol. 2012;107:617-31 pubmed publisher
  • western blot; human
Kishida Y, Natsume A, Toda H, Toi Y, Motomura K, Koyama H, et al. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas. Tumour Biol. 2012;33:373-81 pubmed publisher
  • immunohistochemistry; human; 1:40
Lin J, Wu Y, Chang I. The prognostic impact of O6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: a clinicopathologic and immunohistochemical study of seven cases at a single institution. Indian J Pathol Microbiol. 2011;54:683-7 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:400
Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, et al. Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres. J Oncol. 2011;2011:314962 pubmed publisher
  • immunohistochemistry; human; 1:50
Salehi F, Scheithauer B, Kovacs K, Horvath E, Syro L, Sharma S, et al. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery. 2012;70:491-6; discussion 496 pubmed publisher
  • immunohistochemistry; human; 1:600
Neto J, Carvalho K, Olivieri E, Carraro D, Cunha I, Vassallo J, et al. Evaluation of O6-methylguanine-DNA methyltransferase by immunohistochemistry: best clinical and research practices. Pathol Res Pract. 2011;207:492-7 pubmed publisher
  • immunohistochemistry; human; 1:40
Chang I, Lin J, Wu Y. The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution. J Neurooncol. 2011;105:563-72 pubmed publisher
  • immunohistochemistry; human; 1:20
Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011;28:115-23 pubmed publisher
  • immunohistochemistry; human; 1:2
Araki Y, Mizoguchi M, Yoshimoto K, Shono T, Amano T, Nakamizo A, et al. Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue. Brain Tumor Pathol. 2011;28:25-31 pubmed publisher
  • immunohistochemistry; human; 1:100
Park C, Kim J, Yim S, Lee A, Han J, Kim C, et al. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol. 2011;13:195-202 pubmed publisher
  • immunohistochemistry; human; 1:50
Svrcek M, Buhard O, Colas C, Coulet F, Dumont S, Massaoudi I, et al. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut. 2010;59:1516-26 pubmed publisher
  • western blot; human; 1:200
Faoro D, Von Bueren A, Shalaby T, Sciuscio D, Hürlimann M, Arnold L, et al. Expression of O?-methylguanine-DNA methyltransferase in childhood medulloblastoma. J Neurooncol. 2011;103:59-69 pubmed publisher
  • immunohistochemistry; human; 1:20
Tanaka H, Sasayama T, Nishihara M, Arai A, Kawamura A, Kanomata N, et al. Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. Neurol Med Chir (Tokyo). 2010;50:689-93 pubmed
  • immunohistochemistry; human; 1:40
Guerrero D, Guarch R, Ojer A, Casas J, Méndez Meca C, Esteller M, et al. Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer. Int J Cancer. 2011;128:2853-64 pubmed publisher
  • immunohistochemistry; human; 1:50
Huang S, Lee H, Mar K, Ji D, Huang M, Hsia K. Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:883-9 pubmed publisher
  • immunohistochemistry; human; 1:20
Wu P, Kuo K, Kuo L, Lin Y, Lee W, Lu Y, et al. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer. 2010;68:484-90 pubmed publisher
  • western blot; human; 1:500
Mellai M, Caldera V, Annovazzi L, Chio A, Lanotte M, Cassoni P, et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics. 2009;6:219-27 pubmed
  • western blot; human
Yip S, Miao J, Cahill D, Iafrate A, Aldape K, Nutt C, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622-9 pubmed publisher
  • immunocytochemistry; human; 1:25
  • immunohistochemistry; human; 1:100
Lee A, Kahatapitiya P, Kramer B, Joya J, Hook J, Liu R, et al. Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle. Stem Cells. 2009;27:1098-108 pubmed publisher
  • immunohistochemistry; human; 1:100
Kim J, Suh J, Choi K, Kang H, Shin D, Lee I, et al. Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations. Hum Pathol. 2009;40:934-41 pubmed publisher
  • immunohistochemistry; human; 1:20
Kuo L, Kuo K, Lee M, Wei C, Scaravilli F, Tsai J, et al. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer. 2009;124:2872-9 pubmed publisher
  • immunohistochemistry; human; 1:200
Cho N, Redston M, Zauber A, Carothers A, Hornick J, Wilton A, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008;1:21-31 pubmed publisher
  • immunohistochemistry; human; 1:25
Smith K, Ashby L, Gonzalez L, Gonzalez F, Brachman D, Thomas T, et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed gli. J Neurosurg. 2008;109 Suppl:106-17 pubmed publisher
  • immunohistochemistry; human; 1:25
Kulke M, Hornick J, Frauenhoffer C, Hooshmand S, Ryan D, Enzinger P, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338-45 pubmed publisher
  • western blot; human
Rosati S, Williams R, Nunnally L, McGee M, Sims T, Tracey L, et al. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol Cancer Ther. 2008;7:3852-8 pubmed publisher
  • immunohistochemistry; human; 1:50
Voelter V, Diserens A, Moulin A, Nagel G, Yan P, Migliavacca E, et al. Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. Int J Cancer. 2008;123:1215-8 pubmed publisher
  • immunohistochemistry; human; 1:50
Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou M, Diserens A, et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18:520-32 pubmed publisher
  • western blot; human
Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 2007;37:897-906 pubmed
  • immunohistochemistry; human; 1:25
Sanchez de Abajo A, de la Hoya M, van Puijenbroek M, Tosar A, Lopez Asenjo J, Diaz Rubio E, et al. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res. 2007;13:5729-35 pubmed
  • immunohistochemistry; human; 1:60
Nakasu S, Fukami T, Jito J, Matsuda M. Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol. 2007;68:603-608 pubmed publisher
  • immunohistochemistry; human
Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T. Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol. 2007;5:89 pubmed
  • immunohistochemistry; human
Su P, Lee T, Lin P, Lee P, Jeng Y, Chen C, et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer. 2007;121:1257-64 pubmed
  • western blot; human; 1:1000
Li D, Wang J, Fang Q, Sun H, Xu W, Li W. Protective effect of O6-methylguanine-DNA-methyltransferase on mammalian cells. Chin Med J (Engl). 2007;120:714-7 pubmed
  • immunohistochemistry; human; 1:25
Ogino S, Kawasaki T, Kirkner G, Suemoto Y, Meyerhardt J, Fuchs C. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007;56:1564-71 pubmed
  • immunohistochemistry; human; 1:50
Ogawa T, Yoshida T, Tsuruta T, Saigenji K, Okayasu I. Genetic instability on chromosome 17 in the epithelium of non-polypoid colorectal carcinomas compared to polypoid lesions. Cancer Sci. 2006;97:1335-42 pubmed
  • flow cytometry; mouse; 0.8 ug/time
Kramer B, Lemckert F, Alexander I, Gunning P, McCowage G. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow. J Gene Med. 2006;8:1071-85 pubmed
  • immunohistochemistry; human
Znajda T, Hayashi S, Horton P, Martinie J, Chaudhury P, Marcus V, et al. Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg. 2006;10:483-9 pubmed
  • immunohistochemistry; human; 1:100
Baumann S, Keller G, Pühringer F, Napieralski R, Feith M, Langer R, et al. The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer. 2006;119:264-8 pubmed
  • ELISA; human; 1:100
Fox E, Leahy D, Geraghty R, Mulcahy H, Fennelly D, Hyland J, et al. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J Mol Diagn. 2006;8:68-75 pubmed
  • immunohistochemistry; human; 1:20
Brell M, Tortosa A, Verger E, Gil J, Viñolas N, Villa S, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11:5167-74 pubmed
  • immunohistochemistry; human; 1:100
Higuchi T, Sugihara K, Jass J. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology. 2005;47:32-40 pubmed
  • immunohistochemistry; human; 1:50
  • western blot; human; 1:500
Halford S, Rowan A, Sawyer E, Talbot I, Tomlinson I. O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions. Gut. 2005;54:797-802 pubmed
Zhang Y, Chen Y, Ahsan H, Lunn R, Lee P, Chen C, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer. 2003;103:440-4 pubmed
Liu L, Xu Welliver M, Kanugula S, Pegg A. Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide. Cancer Res. 2002;62:3037-43 pubmed
Xu Welliver M, Pegg A. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis. 2002;23:823-30 pubmed
Wang J, Chen Z, Xia X, Lu D, Xue J, Ruan C. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk Res. 2002;26:281-8 pubmed
Zhang Q, Ohannesian D, Kreklau E, Erickson L. Modulation of 1,3-bis-(2-chloroethyl)-1-nitrosourea resistance in human tumor cells using hammerhead ribozymes designed to degrade O6-methylguanine DNA methyltransferase mRNA. J Pharmacol Exp Ther. 2001;298:141-7 pubmed
Wu M, Kelley M, Hansen W, Martin W. Reduction of BCNU toxicity to lung cells by high-level expression of O(6)-methylguanine-DNA methyltransferase. Am J Physiol Lung Cell Mol Physiol. 2001;280:L755-61 pubmed
product information
Product Type :
Antibody
Product Name :
MGMT Monoclonal Antibody (MT 3.1), Biotin
Catalog # :
MA5-13503
Quantity :
500 µL
Price :
US 487.00
Clonality :
Monoclonal
Purity :
Protein G
Host :
Mouse
Reactivity :
Human
Applications :
Flow Cytometry: Assay-dependent, Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): 1:10-1:20, Western Blot: 0.5-1.0 µg/mL
Species :
Human
Clone :
MT 3.1
Isotype :
IgG1
Storage :
4° C
Description :
O6-Methylguanine-DNA Methyltransferase (MGMT) is an important DNA repair protein involved in tumor cell resistance to the cytostatic activity of chemotherapeutic alkylating agents. This protein is also effective in protecting normal cells against the genotoxic and carcinogenic effects of DNA alkylation. The alkylating drug resistance is caused by MGMT's ability to remove DNA alkyl groups introduced in the O6 position of guanine. MGMT is expressed in highly variable amounts, depending upon the cell and tissue type, species, and cellular growth characteristics. In addition, MGMT activity varies among groups of tumors and within a particular type of tumor.
Immunogen :
Purified recombinant human MGMT protein
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: Assay-dependent, Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): 1:10-1:20, Western Blot: 0.5-1.0 µg/mL
Aliases :
0-6-methylguanine-DNA methyltransferase; 6-O-methylguanine-DNA methyltransferase; Agat; AGT; AI267024; methylated DNA protein cysteine methyltransferase; methylated-DNA--protein-cysteine methyltransferase; methylguanine-DNA methyltransferase; MGMT; O(6)-alkylguanine-DNA alkyltransferase; O-6-alkylguanine-DNA alkyltransferase; O6-alkylguanine-DNA alkyltransferase; O-6-methylguan; O6-methylguanine-DNA methyltranferase; O-6-methylguanine-DNA methyltransferase; O6-methylguanine-DNA methyltransferase; O-6-methylguanine-DNA-alkyltransferase
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA